argenx (NASDAQ:ARGX) Price Target Raised to $680.00

argenx (NASDAQ:ARGX) had its target price upped by equities researchers at Robert W. Baird from $650.00 to $680.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 7.55% from the company’s current price.

Several other research analysts have also commented on ARGX. Wells Fargo & Company lifted their price target on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Piper Sandler increased their price target on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Evercore ISI lifted their price objective on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, HC Wainwright raised their price target on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Stock Up 1.5 %

Shares of ARGX opened at $632.24 on Tuesday. The business has a 50-day simple moving average of $642.62 and a two-hundred day simple moving average of $591.22. The stock has a market cap of $38.42 billion, a price-to-earnings ratio of -717.61 and a beta of 0.58. argenx has a 52 week low of $349.86 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts anticipate that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenx

A number of hedge funds have recently modified their holdings of ARGX. Brucke Financial Inc. acquired a new position in shares of argenx in the fourth quarter worth about $412,000. Mackenzie Financial Corp raised its holdings in argenx by 81.4% in the 4th quarter. Mackenzie Financial Corp now owns 4,449 shares of the company’s stock valued at $2,736,000 after acquiring an additional 1,996 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in argenx during the fourth quarter worth approximately $416,000. Vise Technologies Inc. boosted its position in shares of argenx by 6.8% during the 4th quarter. Vise Technologies Inc. now owns 799 shares of the company’s stock valued at $491,000 after acquiring an additional 51 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in shares of argenx in the 4th quarter valued at approximately $28,510,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.